Typical patterns observed in image plots used to study the association between age, time, and the disease of interest.

<p>Typical patterns observed in image plots used to study the association between age, time, and the disease of interest.</p

Multi-panel graph of salmonellosis in the general Massachusetts population 2004–2005.

<p>Lower left: outcome pyramid; upper right: time-series plot; lower right: image plot.</p

Multi-panel graph of influenza in the United States older adult population (aged 65 and over) 1991–2004.

<p>Lower left: outcome pyramid; upper right: time-series plot; lower right: image plot.</p

Multi-panel graph of asthma in children aged 0–18 in Milwaukee 1997–2006.

<p>Lower left: outcome pyramid; upper right: time-series plot; lower right: image plot.</p

Average estimated glomerular filtration rate in patients during and after telaprevir therapy, by baseline kidney function.

<p>3a. Baseline eGFR ≥ 90 mL/min/1.73m² 3b. Baseline eGFR < 90 mL/min/1.73m². Mean eGFR (solid gray circle) and one-standard deviation error bars are shown with shading at baseline, on treatment (nadir), 12 weeks after finishing telaprevir, while still on PegIFN and RBV, and then one year after completing telaprevir, off all treatment. P < 0.01 for changes between baseline eGFR and eGFR while on telaprevir in both groups. There is no signficant difference between baseline eGFR and eGFR 12 weeks or one year post telaprevir. Fig 3a shows patients with baseline eGFR ≥ 90mL/min/1.73m². (N = 44). 3b.) Includes patients with baseline eGFR < 90mL/min/1.73m² (N = 34). Values that fell outside of one standard deviation are shown with hollow gray circles. eGFR = estimated glomerular filtration rate.</p

Peak rise in serum creatinine during telaprevir therapy.

<p>Bar graphs represent the numbers of patients who experienced a maximum rise in serum creatinine in the above ranges. The majority (55%) of patients experienced a small (< 0.2mg/dl) rise in creatinine during telaprevir therapy. However, thirty-one percent developed significant creatinine rise ≥ 0.3mg/dl, shown by a dashed vertical line.</p

Symptoms contributing to the discontinuation of telaprevir (n = 25).

<p>^{Twenty-five patients discontinued telaprevir therapy. Numbers may add up to more than total N if combinations of multiple symptoms led to discontinuation.}</p><p>^{<b>ϕ -</b> Significant at the level of P < 0.05}</p><p>^{*Other reasons for discontinuation that each affected one patient included fever and noncomplicance.}</p><p>Symptoms contributing to the discontinuation of telaprevir (n = 25).</p

Univariate and multivariable linear regression model predicting change in eGFR over one year follow-up.

<p>^{Abbreviations: HIV = human immunodeficiency virus, eGFR = estimated glomerular filtration rate}</p><p>Univariate and multivariable linear regression model predicting change in eGFR over one year follow-up.</p

Univariate and multivariable logistic regression model predicting development of significant creatinine rise during therapy with telaprevir.

<p>^{Abbreviations: HIV = human immunodeficiency virus, eGFR = estimated glomerular filtration rate}</p><p>Univariate and multivariable logistic regression model predicting development of significant creatinine rise during therapy with telaprevir.</p

Timeline of Triple Therapy, Short and Long-term Follow-up.

<p>Patients were prescribed triple therapy (telaprevir, Peg-IFN, and ribavirin) for twelve weeks. Based on clinical characteristics and at the providers discretion patients then continue Peg-IFN and ribavirin for a total of 24–48 weeks. Short-term follow-up was obtained 12 weeks after telaprevir was discontinued (at week 24). Long-term follow-up was obtained 12 months after telaprevir was discontinued (at week 62).</p